Associated Papers
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Patient tissue-derived FGFR4-variant and wild-type colorectal cancer organoid development and anticancer drug sensitivity testing.
Lin H et al.
Heliyon, 2024
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.
Boyd DC et al.
Cancers, 2023
Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A et al.
Cancer Biomarkers : Section a of Disease Markers, 2023
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ et al.
Breast Cancer Research : Bcr, 2021
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA et al.
British Journal of Cancer, 2021
FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis.
Kim JH et al.
Frontiers in Oncology, 2021
FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM et al.
Pharmacology & Therapeutics, 2020
FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.
Turunen SP et al.
Cell Death and Differentiation, 2019
A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
Tyran M et al.
Cancers, 2019
Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis.
Mikhaylenko DS et al.
Biochemistry. Biokhimiia, 2018
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS et al.
Molecular Cancer Therapeutics, 2017
Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport.
Sneddon WB et al.
The Journal of Biological Chemistry, 2016
Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D et al.
Plos One, 2016
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.
Yu M et al.
Science (new York, N.y.), 2014
Fibroblast growth factor receptors, developmental corruption and malignant disease.
Kelleher FC et al.
Carcinogenesis, 2013
Physical-chemical principles underlying RTK activation, and their implications for human disease.
He L et al.
Biochimica Et Biophysica Acta, 2012
Targeting mutant fibroblast growth factor receptors in cancer.
Greulich H et al.
Trends in Molecular Medicine, 2011
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.
Roidl A et al.
Oncogene, 2010
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.
Ruhe JE et al.
Cancer Research, 2007